MS IVIG is made from human blood plasma. Stricter donor guidelines and the US Food and Drug Administration (FDA) mandated cleansing (being treated with detergents and solvents that kill organisms) of the blood being processed has virtually eliminated the risk of cross-contamination of Hepatitis B, Hepatitis C and HIV. The final product is a freeze-dried powder that is infused after it is mixed with sterile water. It should be noted that multiple sclerosis IVIG for the specific treatment of MS has not yet been approved by the FDA. It has been approved for use with 6 specific conditions. It may be authorized by doctors, meaning insurance companies will cover the expense, if it is proven other methods (eg. Avonex, Betaseron, Copaxone, Methotrexate, or steroids) have failed to achieve the desired results in treating MS patients.

MS IVIG is given every 3-4 weeks because that is the life-expectancy of the antibodies …

Since the 1980’s, there has been considerable hope MS IVIg treatments, or one of the other immunosuppressive agents could possibly successfully treat MS.  Some of them have worked well, others have not. Multiple Sclerosis IVIg was once promising.  Some of that initial hope has faded. For the most part the treatments for MS have evolved from immunosuppressive steroids and chemotherapy to the immunomodulators like Avonex, Betaseron, and Copaxone.  Despite initial positive indications, these treatments have been mostly disappointing.  And most of the long-term effects have been acutely toxic over long periods.  It is now determined that these treatments should only be used in very select circumstances and patients.  Multiple Sclerosis IVIg was once promising.  Intravenous immunoglobulin G (IVIg) was once thought to reduce the clinical attack rate.  But the initial trials involved only small numbers of patients, therefore once more comprehensive studies were conducted have challenged the validity of …